Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma
Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer…
Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma
Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its legacy products for multiple myeloma. The post Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma appeared first on MedCity News.
Healthcare Keeps Buying AI. But Nobody’s Building the Workforce to Run It.
Most younger professionals entering the workforce have little visibility into interoperability, digital health infrastructure, or healthcare data architecture as career pathways. The post Healthcare Keeps Buying AI. But Nobody’s Building the Workforce to Run It. appeared first on MedCity News.
Analysis: At Least 37 States Have Medicaid State Directed Payments for Hospital Services That Could Be Reduced by the 2025 Reconciliation Law Limits
An estimated $60 billion in federal Medicaid spending in 37 states (including the District of Columbia) would likely exceed new federal limits on state directed payments for hospital services once fully implemented, a new KFF analysis finds. States with the biggest potential reductions in Medicaid payments to hospitals include California, Illinois, Kentucky, Texas, North Carolina,…
At Least 37 States Have Medicaid State Directed Payments for Hospital Services That Could Be Reduced by the 2025 Reconciliation Law Limits
This analysis estimates the number of states impacted by and the amount of current federal spending on Medicaid state directed payments for hospital services that exceeds the new limits established by the 2025 reconciliation law when fully implemented.
Optional Medicaid and CHIP Coverage for Lawfully Present Immigrant Children Could Mitigate Coverage Losses Due to 2025 Reconciliation Law
This brief provides an overview of health coverage of noncitizen children to provide greater insight into the potential role of Immigrant Children’s Health Improvement Act (ICHIA) coverage in limiting the 2025 reconciliation law’s impact on coverage for lawfully present immigrant children.
My Husband Was Kicked Out of Hospice for Dying Too Slowly
“No more operations,” he said. It was mid-January 2026, and my then-73-year-old husband, Mike Salmon, had just started bouncing back from a three-month ordeal of three operations related to aortic aneurysms, sepsis, and a terrifying descent into delirium tied to a stay in the intensive care unit. Now, after another potentially fatal aortic aneurysm and…
Trump Team’s Use of Arcane Budget Rule Threatens Medicaid Coverage
About 200,000 low-income Arkansans could see major changes to their health coverage next year after the Trump administration recently informed state officials it will not renew a key Medicaid agreement with the federal government. The decision by federal officials, citing authority granted under President Donald Trump’s signature tax-and-spending law, suggests the GOP-led state’s predicament could…
Appeals Court Sides with Providers in No Surprises Act Pay Dispute
A court ruling struck down key parts of how regulators calculate the No Surprises Act’s qualifying payment amount, siding with the Texas Medical Association’s argument that the formula has historically favored payers in arbitration. The post Appeals Court Sides with Providers in No Surprises Act Pay Dispute appeared first on MedCity News.
Cotiviti Launches AI Solution to Address Coordination of Benefits Issues
Cotiviti launched an AI-powered coordination of benefits solution that uses enrollment data to identify and resolve coverage issues before claims are submitted. The post Cotiviti Launches AI Solution to Address Coordination of Benefits Issues appeared first on MedCity News.
PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy
Sangamo Therapeutics filed for Chapter 11 bankruptcy in June after its search for strategic alternatives failed to find a path forward for the company. PTC Therapeutics’ auction win brings a Sangamo gene therapy candidate for Fabry disease, a rare inherited disorder with few treatment options. The post PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for…
